Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Previously Presented) A compound of the formula



wherein:

x is from 0 to 2;

R^1 is selected from the group consisting of hydroxy, C_1 to C_9 alkoxy (optionally substituted by halo), C_1 to C_9 cycloalkylalkoxy (wherein the cycloalkyl group is optionally substituted by C_1 to C_4 alkyl or halo, and the alkoxy group is optionally substituted by halo), arylalkoxy (wherein the aryl group is optionally substituted by C_1 to C_4 alkyl, C_1 to C_3 alkoxy or halo, and the alkoxy group is optionally substituted by halo) and C_1 to C_9 alkyl amino (wherein the alkyl group is optionally substituted by halo)

R^2 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl and cycloalkylalkyl, wherein alkyl moieties are optionally substituted by halo, and aryl groups are optionally substituted by C_1 to C_4 alkyl, C_1 to C_4 alkoxy and halo,

R^3 is absent when -Y-Z-R^2 is attached to N, or R^3 is selected from the group consisting of H, C_1 to C_7 alkyl and benzyl, when

-Y-Z-R^2 is not attached to N;

Y is C_2 to C_{10} alkylene, in which one non-terminal carbon atom may be replaced by O; and

Z is



wherein R^5, R^6 and R^7 are independently H, aryl (C_1 to C_3) alkyl or cycloalkyl (C_1 to C_3) alkyl optionally substituted by halo, and Q is H or methyl, provided that when Z is



at least one of R^5 and R^7 is aryl(C_1 to C_3)alkyl or cycloalkyl(C_1 to C_3)alkyl, optionally substituted by halo;

or a pharmaceutically acceptable salt thereof.

2. (Cancelled)

3. (Currently Amended, Withdrawn) The compound of claim 1 ~~or 30~~ wherein R^2 is selected from phenyl, halophenyl, benzyl, halobenzyl, phenylethyl, halophenylethyl, phenylpropyl, halophenylpropyl, phenylbutyl, halophenylbutyl, tolyl, methoxybenzyl, trifluoromethylbenzyl, halo-methoxybenzyl, phenylbenzyl, adamantanemethyl, adamantaneethyl, adamantanepropyl, cyclohexanemethyl, cyclohexaneethyl, and naphthyl.

4. (Currently Amended, Withdrawn) The compound of claim 1 ~~or 30~~ wherein x is 0.

5. (Currently Amended, Withdrawn) The compound of claim 1 ~~or 30~~ wherein x is 1 or 2, and R^1 is selected from hydroxy, C_1 to C_9 alkoxy (optionally substituted by halo), C_1 to C_9 cycloalkylalkoxy (wherein the cycloalkyl group is optionally substituted by C_1 to C_4 alkyl or halo, and the alkoxy group is optionally substituted by halo), arylalkoxy (wherein the aryl group is optionally substituted by C_1 to C_4 alkyl, C_1 to C_3 alkoxy or halo, and the alkoxy

group is optionally substituted by halo) and C_1 to C_9 alkylamino wherein the alkyl group is optionally substituted by halo.

6.-7. (Cancelled)

8. (Withdrawn) The compound of claim 1, wherein Y is propylene, butylene, pentylene, hexylene, heptylene, octylene or nonylene.

9.-12. (Cancelled)

13. (Withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1, and a physiologically acceptable diluent or carrier.

14.-30. (Canceled)

31. (Currently Amended, Withdrawn) A method of treating a patient in need of a sedative, a sleep regulator, an anticonvulsant, a regulator of hypothalamo-hypophyseal secretion, an antidepressant, a modulator of cerebral circulation, treatment of asthma or treatment of irritable bowel syndrome comprising administering to said patient a therapeutically effective amount of H_3 receptor ligand or a pharmaceutically acceptable salt thereof **according to claim 1**~~**, said H_3 receptor ligand being a compound of the formula**~~



~~**wherein**~~

~~**x is from 0 to 2;**~~

~~**R^1 is selected from the group consisting of hydroxy, C_1 to C_9 alkoxy (optionally substituted by halo), C_1 to C_9 cycloalkylalkoxy (wherein the cycloalkyl group is optionally substituted by C_1 to C_4 alkyl or halo, and the alkoxy group is optionally**~~

~~substituted by halo), arylalkoxy (wherein the aryl group is optionally substituted by C_1 to C_4 alkyl, C_1 to C_3 alkoxy or halo, and the alkoxy group is optionally substituted by halo) and C_1 to C_9 alkyl amino (wherein the alkyl group is optionally substituted by halo)~~

~~R^2 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl and cycloalkylalkyl, wherein alkyl moieties are optionally substituted by halo, and aryl groups are optionally substituted by C_1 to C_4 alkyl, C_1 to C_4 alkoxy and halo,~~

~~R^3 is absent when -Y-Z-R^2 is attached to N, or R^3 is selected from the group consisting of H, C_1 to C_7 alkyl and benzyl, when~~

~~-Y-Z-R^2 is not attached to N;~~

~~Y is C_2 to C_{10} alkylene, in which one non-terminal carbon atom may be replaced by O; and~~

~~Z is~~



~~wherein R^5, R^6 and R^7 are independently H, aryl (C_1 to C_3) alkyl or cycloalkyl (C_1 to C_3) alkyl optionally substituted by halo, and Q is H or methyl, or Q is linked to R^5 or R^7 to form a five-membered ring or Q is linked to R^2 to form a six-membered ring, provided that when Z is~~



~~at least one of R^5 and R^7 is aryl(C_1 to C_3)alkyl or cycloalkyl(C_1 to C_3)alkyl, optionally substituted by halo;~~

~~or a pharmaceutically acceptable salt thereof~~.

32. (Withdrawn) The method of claim 31, wherein R^2 is selected from phenyl, halophenyl, benzyl, halobenzyl, phenylethyl, halophenylethyl, phenylpropyl, halophenylpropyl, phenylbutyl, halophenylbutyl, tolyl, methoxybenzyl, trifluoromethylbenzyl, halo-methoxybenzyl, phenylbenzyl, adamantanemethyl, adamantaneethyl, adamantanepropyl, cyclohexanemethyl, cyclohexaneethyl, and naphthyl.

33. (Withdrawn) The method of claim 31, wherein x is 0.

34. (Withdrawn) The method of claim 31, wherein x is 1 or 2, and R^1 is selected from hydroxy, C_1 to C_9 alkoxy (optionally substituted by halo), C_1 to C_9 cycloalkylalkoxy (wherein the cycloalkyl group is optionally substituted by C_1 to C_4 alkyl or halo, and the alkoxy group is optionally substituted by halo), arylalkoxy (wherein the aryl group is optionally substituted by C_1 to C_4 alkyl, C_1 to C_3 alkoxy or halo, and the alkoxy group is optionally substituted by halo) and C_1 to C_9 alkylamino wherein the alkyl group is optionally substituted by halo.

35. (Withdrawn) The method of claim 31, wherein Y is propylene, butylene, pentylene, hexylene, heptylene, octylene or nonylene.